Select Publications
Journal articles
2021, 'The management of HER2-positive early breast cancer: Current and future therapies', Asia-Pacific Journal of Clinical Oncology, 17, pp. 3 - 12, http://dx.doi.org/10.1111/ajco.13655
,2021, 'Case Report: Paclitaxel-Induced Pneumonitis in Early Breast Cancer: A Single Institution Experience and Review', Frontiers in Oncology, 11, http://dx.doi.org/10.3389/fonc.2021.701424
,2021, 'A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER plus advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.1050
,2021, 'acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician's choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.TPS1100
,2021, 'Australian real-world outcomes of ribociclib and aromatase inhibitor in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC): Results from Kisqali Access Registry for Metastatic breast cancer in Australia (KARMA) collected alongside a medicine access program.', Journal of Clinical Oncology, 39, pp. e13018 - e13018, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e13018
,2021, 'Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.', Journal of Clinical Oncology, 39, pp. 1020 - 1020, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.1020
,2021, 'Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC).', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.1017
,2021, 'Molecular biomarkers for contemporary therapies in hormone receptor‐positive breast cancer', Genes, 12, pp. 1 - 24, http://dx.doi.org/10.3390/genes12020285
,2021, 'The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer', Nature Medicine, 27, pp. 310 - 320, http://dx.doi.org/10.1038/s41591-020-01168-7
,2021, 'CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care', Asia-Pacific Journal of Clinical Oncology, 17, pp. 3 - 14, http://dx.doi.org/10.1111/ajco.13555
,2021, 'Epigenetic therapy targets the 3D epigenome in endocrine-resistant breast cancer', , http://dx.doi.org/10.1101/2021.06.21.449340
,2020, 'Estrogen receptor positive breast cancer patient–derived xenograft models in translational research', Current Opinion in Endocrine and Metabolic Research, 15, pp. 31 - 36, http://dx.doi.org/10.1016/j.coemr.2020.10.004
,2020, 'Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer', Asia-Pacific Journal of Clinical Oncology, 16, pp. 3 - 14, http://dx.doi.org/10.1111/ajco.13461
,2020, 'Stromal cell diversity associated with immune evasion in human triple-negative breast cancer', EMBO Journal, 39, pp. e104063, http://dx.doi.org/10.15252/embj.2019104063
,2020, 'Testosterone therapy considerations in oestrogen, progesterone and androgen receptor–positive breast cancer in a transgender man', Clinical Endocrinology, 93, pp. 355 - 357, http://dx.doi.org/10.1111/cen.14263
,2020, 'MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer', Breast Cancer Research, 22, pp. 87, http://dx.doi.org/10.1186/s13058-020-01318-2
,2020, 'MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer', , http://dx.doi.org/10.1101/2020.06.09.140921
,2020, 'Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer', Breast Cancer Research, 22, http://dx.doi.org/10.1186/s13058-020-01306-6
,2020, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', bioRxiv, http://dx.doi.org/10.1101/2020.06.04.135277
,2020, 'Single-cell analysis reveals diverse stromal subsets associated with immune evasion in triple-negative breast cancer', bioRxiv, http://dx.doi.org/10.1101/2020.06.04.135327
,2020, 'A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.', Journal of Clinical Oncology, 38, pp. 1023 - 1023, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1023
,2020, 'Targeting CDK2 in cancer: challenges and opportunities for therapy', Drug Discovery Today, 25, pp. 406 - 413, http://dx.doi.org/10.1016/j.drudis.2019.12.001
,2020, 'Cyclin E1 and cyclin E2 in ER+ breast cancer: Prospects as biomarkers and therapeutic targets', Endocrine-Related Cancer, 27, pp. R93 - R112, http://dx.doi.org/10.1530/ERC-19-0501
,2020, 'Window of opportunity treatment in breast cancer', ANZ Journal of Surgery, 90, pp. 34 - 40, http://dx.doi.org/10.1111/ans.15487
,2020, '9. Factors influencing the success rate of patient derived xenograft formation from breast cancer specimens', Pathology, 52, pp. S136 - S136, http://dx.doi.org/10.1016/j.pathol.2020.01.010
,2019, 'Expression of the interleukin-3/receptor complex by breast cancer cells promotes vascular mimicry via a PI3K-dependent mechanism and is associated with poor outcome', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p005
,2019, 'Single-cell transcriptomics reveals marked heterogeneity for intrinsic molecular subtype and cellular function in estrogen receptor positive breast cancer', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p045
,2019, 'Unravelling the role of cell plasticity in BrCa development and metastasis', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p040
,2019, 'Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary', Medical Journal of Australia, 211, pp. 224 - 229, http://dx.doi.org/10.5694/mja2.50280
,2019, 'The international academy of cytology yokohama system for reporting breast fine-needle aspiration biopsy cytopathology', Acta Cytologica, 63, pp. 257 - 273, http://dx.doi.org/10.1159/000499509
,2019, 'Immunoprofiling of breast cancer antigens using antibodies derived from local lymph nodes', Cancers, 11, http://dx.doi.org/10.3390/cancers11050682
,2019, 'Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer', Breast Cancer Research, 21, http://dx.doi.org/10.1186/s13058-019-1127-y
,2019, 'The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis', Breast Cancer Research and Treatment, 174, pp. 271 - 278, http://dx.doi.org/10.1007/s10549-018-5054-x
,2019, 'Non-canonical AR activity facilitates endocrine resistance in breast cancer', Endocrine-Related Cancer, 26, pp. 251 - 264, http://dx.doi.org/10.1530/ERC-18-0333
,2019, 'Estrogen receptor signaling is reprogrammed during breast tumorigenesis', Proceedings of the National Academy of Sciences of the United States of America, 166, pp. 11437 - 11443, http://dx.doi.org/10.1073/pnas.1819155116
,2019, 'Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer', Endocrine-Related Cancer, 26, pp. R15 - R30, http://dx.doi.org/10.1530/ERC-18-0317
,2019, 'The IAC Yokohama system for reporting breast FNAB cytology', Acta Cytologica, 63, pp. 257 - 273, http://dx.doi.org/10.1159/000499509
,2019, 'The proliferative and apoptotic landscape of basal-like breast cancer', International Journal of Molecular Sciences, 20, http://dx.doi.org/10.3390/ijms20030667
,2018, 'A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexes', Nature Communications, 9, http://dx.doi.org/10.1038/s41467-018-04619-5
,2018, 'Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer', Nature Communications, 9, pp. 2897, http://dx.doi.org/10.1038/s41467-018-05220-6
,2018, 'Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial', The Lancet Oncology, 19, pp. 1385 - 1393, http://dx.doi.org/10.1016/S1470-2045(18)30380-2
,2018, 'Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer', Asia-Pacific Journal of Clinical Oncology, 14, pp. 12 - 21, http://dx.doi.org/10.1111/ajco.13065
,2018, 'Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm', Asia-Pacific Journal of Clinical Oncology, 14, pp. 3 - 11, http://dx.doi.org/10.1111/ajco.13064
,2018, 'Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia', Clinical Endocrinology, 89, pp. 280 - 296, http://dx.doi.org/10.1111/cen.13735
,2018, 'Attitudes of patients with metastatic cancer towards research biopsies', Asia-Pacific Journal of Clinical Oncology, 14, pp. 231 - 238, http://dx.doi.org/10.1111/ajco.12783
,2018, 'Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling', Nature Medicine, 24, pp. 463 - 473, http://dx.doi.org/10.1038/nm.4494
,2018, 'Erratum: Correction: MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells (eLife (2014) 3 (e01763) PII: e36414)', eLife, 7, http://dx.doi.org/10.7554/eLife.36414
,2018, 'Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy', EBioMedicine, 29, pp. 166 - 176, http://dx.doi.org/10.1016/j.ebiom.2018.01.041
,2017, 'Endocrine therapy for breast cancer: A Renaissance', The Endocrinologist, pp. 13 - 14
,2017, 'Secreted Tumor Antigens – Immune Biomarkers for Diagnosis and Therapy', Proteomics, 17, http://dx.doi.org/10.1002/pmic.201600442
,